Uniting Wealth Partners LLC Sells 1,495 Shares of Pfizer Inc. (NYSE:PFE)

Uniting Wealth Partners LLC lowered its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,844 shares of the biopharmaceutical company’s stock after selling 1,495 shares during the quarter. Uniting Wealth Partners LLC’s holdings in Pfizer were worth $655,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also bought and sold shares of PFE. Confluence Wealth Services Inc. lifted its holdings in shares of Pfizer by 11.3% in the 1st quarter. Confluence Wealth Services Inc. now owns 79,921 shares of the biopharmaceutical company’s stock worth $2,025,000 after acquiring an additional 8,143 shares during the last quarter. Jeppson Wealth Management LLC increased its stake in Pfizer by 8.3% in the 1st quarter. Jeppson Wealth Management LLC now owns 33,115 shares of the biopharmaceutical company’s stock worth $839,000 after buying an additional 2,548 shares during the period. Tsfg LLC raised its holdings in shares of Pfizer by 43.0% in the 1st quarter. Tsfg LLC now owns 5,830 shares of the biopharmaceutical company’s stock valued at $148,000 after purchasing an additional 1,752 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in shares of Pfizer by 38.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 1,182,830 shares of the biopharmaceutical company’s stock valued at $29,027,000 after purchasing an additional 330,019 shares in the last quarter. Finally, BSW Wealth Partners raised its holdings in shares of Pfizer by 32.6% in the 1st quarter. BSW Wealth Partners now owns 70,209 shares of the biopharmaceutical company’s stock valued at $1,779,000 after purchasing an additional 17,274 shares in the last quarter. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

PFE has been the subject of several recent research reports. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a report on Monday, March 10th. The Goldman Sachs Group reiterated a “neutral” rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a research note on Tuesday, April 8th. Citigroup reiterated a “neutral” rating on shares of Pfizer in a research note on Thursday, March 27th. Cantor Fitzgerald assumed coverage on shares of Pfizer in a research note on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price objective for the company. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have assigned a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $29.17.

Pfizer Stock Down 0.2%

NYSE:PFE opened at $24.20 on Friday. The company has a market cap of $137.56 billion, a PE ratio of 17.53, a P/E/G ratio of 0.88 and a beta of 0.57. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. The company’s 50 day moving average is $23.46 and its two-hundred day moving average is $24.85.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.67 by $0.25. The company had revenue of $13.72 billion for the quarter, compared to the consensus estimate of $14.43 billion. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. Pfizer’s revenue was down 7.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.82 EPS. Analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 7.11%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer’s dividend payout ratio (DPR) is currently 124.64%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.